7th Circ. To Crawl Into Humira 'Patent Thicket' Dispute
The Seventh Circuit could dramatically affect the intellectual property landscape for biologic drugs after hearing oral arguments on Thursday from Humira buyers accusing AbbVie of wrongly employing a "patent thicket" to...To view the full article, register now.
Already a subscriber? Click here to view full article